Afrezza (insulin human) Inhalation Powder + insulin degludec

ApprovedCompleted
0 watching 0 views this week🔥 Hot
80
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Type 1 Diabetes

Conditions

Type 1 Diabetes

Trial Timeline

Mar 31, 2022 → Oct 17, 2022

About Afrezza (insulin human) Inhalation Powder + insulin degludec

Afrezza (insulin human) Inhalation Powder + insulin degludec is a approved stage product being developed by MannKind Corp for Type 1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT05243628. Target conditions include Type 1 Diabetes.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05243628ApprovedCompleted